MGI PHARMA to Present at the Robert W. Baird 2005 Growth Stock Conference
05 Mayo 2005 - 6:00AM
Business Wire
MGI PHARMA, INC. (Nasdaq:MOGN) today announced that it will present
at the Robert W. Baird 2005 Growth Stock Conference on Thursday,
May 12, at 1:00 p.m. Eastern Time. Lonnie Moulder, president and
chief executive officer of MGI PHARMA, will give the presentation,
which will be webcast live over the Internet. The conference will
be held at the Four Seasons Hotel in Chicago. -0- *T What: MGI
PHARMA's presentation at the Robert W. Baird 2005 Growth Stock
Conference When: Thursday, May 12, 2005 at 1:00 p.m. Eastern Time
How: Live over the Internet - simply log on to www.mgipharma.com.
In addition to the live webcast, the presentation will be archived
on the Company's web site for one month. *T About MGI PHARMA MGI
PHARMA, INC. is an oncology-focused biopharmaceutical company that
acquires, develops and commercializes proprietary products that
address the unmet needs of cancer patients. MGI PHARMA has a
portfolio of proprietary pharmaceuticals, and intends to become a
leader in oncology. MGI PHARMA markets Aloxi(R) (palonosetron
hydrochloride) injection, Kadian(R) (sustained release morphine
sulfate) capsules, Salagen(R) Tablets (pilocarpine hydrochloride)
and Hexalen(R) (altretamine) capsules in the United States. The
Company directly markets its products in the U.S. and collaborates
with partners to reach international markets. For more information
about MGI PHARMA, please visit www.mgipharma.com. This news release
contains certain "forward-looking" statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements are typically preceded by words such as "believes," "
expects," "anticipates," "intends," "will," "may," "should," or
similar expressions. These forward-looking statements are not
guarantees of MGI PHARMA's future performance and involve a number
of risks and uncertainties that may cause actual results to differ
materially from the results discussed in these statements. Factors
that might cause the Company's results to differ materially from
those expressed or implied by such forward-looking statements
include, but are not limited to, the ability of MGI PHARMA's
product candidates to be proven safe and effective in humans, to
receive marketing authorization from regulatory authorities, and to
ultimately compete successfully with other therapies; continued
sales of MGI PHARMA's marketed products; development or acquisition
of additional products; reliance on contract manufacturing; changes
in strategic alliances; continued access to capital; and other
risks and uncertainties detailed from time to time in the Company's
filings with the Securities and Exchange Commission including its
most recently filed Form 10-Q or 10-K. MGI PHARMA undertakes no
duty to update any of these forward-looking statements to conform
them to actual results.
Mgi Pharma (MM) (NASDAQ:MOGN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Mgi Pharma (MM) (NASDAQ:MOGN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Mgi Pharma (MM) (NASDAQ): 0 recent articles
Más de MGI PHARMA, INC. Artículos de Noticias